(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
A Manual for Pick Great Lawful Discussion Administrations For New businesses In 2024- IDF, police arrest eleven for criminal, terror-related activity over weekend
- Orcas seen hunting great white sharks to eat their livers in drone footage recorded in Mexico
- The next frontier in space is closer than you think – welcome to the world of very low Earth orbit satellites
- The Specialty of Compromise: Examples from Reality
- The Response to Self-improvement: Embracing a Development Outlook
- Key Caper d: A Survey of \Procedure and Tomfoolery Released\ Tabletop game
- Electric discovery on Mars! Scientists find tiny lightning bolts coming from Red Planet dust clouds
- Sea level doesn’t rise at the same rate everywhere – we mapped where Antarctica’s ice melt would have the biggest impact
